Jun Ohsugi
Fukushima Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jun Ohsugi.
Scientific Reports | 2015
Yu Abe; Tomisato Miura; Mitsuaki Yoshida; Risa Ujiie; Yumiko Kurosu; Nagisa Kato; Atsushi Katafuchi; Naohiro Tsuyama; Takashi Ohba; Tomoko Inamasu; Fumio Shishido; Hideyoshi Noji; Kazuei Ogawa; Hiroshi Yokouchi; Kenya Kanazawa; Takashi Ishida; Satoshi Muto; Jun Ohsugi; Hiroyuki Suzuki; Tetsuo Ishikawa; Kenji Kamiya; Akira Sakai
Excess risk of leukemia and brain tumors after CT scans in children has been reported. We performed dicentric chromosome assay (DCAs) before and after CT scan to assess effects of low-dose ionizing radiation on chromosomes. Peripheral blood (PB) lymphocytes were collected from 10 patients before and after a CT scan. DCA was performed by analyzing either 1,000 or 2,000 metaphases using both Giemsa staining and centromere-fluorescence in situ hybridization (Centromere-FISH). The increment of DIC formation was compared with effective radiation dose calculated using the computational dosimetry system, WAZA-ARI and dose length product (DLP) in a CT scan. Dicentric chromosome (DIC) formation increased significantly after a single CT scan, and increased DIC formation was found in all patients. A good correlation between the increment of DIC formation determined by analysis of 2,000 metaphases using Giemsa staining and those by 2,000 metaphases using Centromere-FISH was observed. However, no correlation was observed between the increment of DIC formation and the effective radiation dose. Therefore, these results suggest that chromosome cleavage may be induced by one CT scan, and we recommend 2,000 or more metaphases be analyzed in Giemsa staining or Centromere-FISH for DCAs in cases of low-dose radiation exposure.
Human Vaccines & Immunotherapeutics | 2014
Hiroyuki Suzuki; Yuki Owada; Yuzuru Watanabe; Takuya Inoue; Mitsuro Fukuharav; Takumi Yamaura; Satoshi Mutoh; Naoyuki Okabe; Hiroshi Yaginuma; Takeo Hasegawa; Atsushi Yonechi; Jun Ohsugi; Mika Hoshino; Mitsunori Higuchi; Yutaka Shio; Mitsukazu Gotoh
Despite of recent development in the field of molecular targeted therapies, lung cancer is a leading cause of cancer death in the world. Remarkable progress has been made recently in immunotherapy for patients with non-small-cell lung cancer (NSCLC), with several modalities, concepts, and treatment settings being investigated. In vaccine development, large-scale clinical trials such as those with L-BLP25, belagenpumatucel-L, TG4010, and talactoferrin are already ongoing and some results have been reported. A trial of a vaccine as adjuvant therapy for patients with completely resected NSCLC is also ongoing with one of the major cancer-testis antigens, melanoma-associated antigen (MAGE)-A3. More recently, the effectiveness of multiple peptide vaccines has also been shown. Recently developed unique treatment modalities are the immune checkpoint inhibitors, such as antibodies against PD-1 and PD-L1, which also show promise. However, although therapeutic cancer vaccines are generally thought to be safe, severe adverse events should be monitored carefully when using immune checkpoint inhibitors. Here, we discuss recent advances and future perspectives of immunotherapy for patients with NSCLC.
Journal of Radiation Research | 2016
Yu Abe; Tomisato Miura; Mitsuaki Yoshida; Risa Ujiie; Yumiko Kurosu; Nagisa Kato; Atsushi Katafuchi; Naohiro Tsuyama; Fumihiko Kawamura; Takashi Ohba; Tomoko Inamasu; Fumio Shishido; Hideyoshi Noji; Kazuei Ogawa; Hiroshi Yokouchi; Kenya Kanazawa; Takashi Ishida; Satoshi Muto; Jun Ohsugi; Hiroyuki Suzuki; Tetsuo Ishikawa; Kenji Kamiya; Akira Sakai
We recently reported an increase in dicentric chromosome (DIC) formation after a single computed tomography (CT) scan (5.78–60.27 mSv: mean 24.24 mSv) and we recommended analysis of 2000 metaphase cells stained with Giemsa and centromere-FISH for dicentric chromosome assay (DCA) in cases of low-dose radiation exposure. In the present study, we analyzed the frequency of chromosome translocations using stored Carnoys-fixed lymphocyte specimens from the previous study; these specimens were from 12 patients who were subject to chromosome painting of Chromosomes 1, 2 and 4. Chromosomes 1, 2 and 4 were analyzed in ∼5000 cells, which is equivalent to the whole-genome analysis of almost 2000 cells. The frequency of chromosome translocation was higher than the number of DICs formed, both before and after CT scanning. The frequency of chromosome translocations tended to be higher, but not significantly higher, in patients with a treatment history compared with patients without such a history. However, in contrast to the results for DIC formation, the frequency of translocations detected before and after the CT scan did not differ significantly. Therefore, analysis of chromosome translocation may not be a suitable assay for detecting chromosome aberrations in cases of low-dose radiation exposure from a CT scan. A significant increase in the frequency of chromosome translocations was not likely to be detected due to the high baseline before the CT scan; the high and variable frequency of translocations was probably due to multiple confounding factors in adults.
Journal of Thoracic Oncology | 2018
Yuki Owada-Ozaki; Satoshi Muto; Hironori Takagi; Takuya Inoue; Yuzuru Watanabe; Mitsuro Fukuhara; Takumi Yamaura; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Jun Ohsugi; Mika Hoshino; Yutaka Shio; Hideaki Nanamiya; Jun-ichi Imai; Takao Isogai; Shinya Watanabe; Hiroyuki Suzuki
Introduction: Tumor mutation burden (TMB) is thought to be associated with the amount of neoantigen in the tumor and to have an important role in predicting the effect of immune checkpoint inhibitors. However, the relevance of TMB to prognosis is not yet fully understood. In this study, we investigated the clinical significance of TMB in patients with NSCLC and examined the relationship between TMB and prognosis. Methods: We calculated TMB within individual tumors by whole‐exome sequencing analysis using next‐generation sequencing. We included that there were 90 patients with NSCLC who underwent surgery in the Hospital of Fukushima Medical University from 2013 to 2016. No patients received chemotherapy or immunotherapy before surgery. We assessed the correlation between TMB and prognosis. Results: TMB greater than 62 was associated with worse overall survival (OS) of patients with NSCLC (hazard ratio [HR] = 6.633, p = 0.0003). Multivariate analysis showed poor prognosis with high TMB (HR = 12.31, p = 0.019). In patients with stage I NSCLC, higher TMB was associated with worse prognosis for both OS (HR = 7.582, p = 0.0018) and disease‐free survival (HR = 6.07, p = 0.0072). Conclusions: High TMB in NSCLC is a poor prognostic factor. If high TMB is a predictor of the efficacy of immune checkpoint inhibitors, postoperative adjuvant therapy with immune checkpoint inhibitors may contribute to improvement of recurrence and OS.
Cancer Letters | 2006
Hiroyuki Suzuki; Takanori Kawaguchi; Takeo Hasegawa; Atsushi Yonechi; Jun Ohsugi; Mitsunori Higuchi; Fumihiko Yamada; Yutaka Shio; Koichi Fujiu; Ryuzo Kanno; Akio Ohishi; Mitsukazu Gotoh
Lung Cancer | 2007
Yutaka Shio; Hiroyuki Suzuki; Takanori Kawaguchi; Jun Ohsugi; Mitsunori Higuchi; Koichi Fujiu; Ryuzo Kanno; Akio Ohishi; Mitsukazu Gotoh
Fukushima journal of medical science | 2003
Koichi Fujiu; Ryuzo Kanno; Hiroyuki Suzuki; Yutaka Shio; Mitsunori Higuchi; Jun Ohsugi; Akio Oishi; Mitsukazu Gotoh
Haigan | 2002
Hiroyuki Suzuki; Yutaka Shio; Jun Ohsugi; Mitsunori Higuchi; Koichi Fujiu; Ryuzo Kanno; Akio Ohishi; Mitsukazu Gotoh
The Journal of The Japanese Association for Chest Surgery | 2001
Mitsunori Higuchi; Jun Ohsugi; Yutaka Shio; Hiroyuki Suzuki; Koichi Fujiu; Ryuzo Kanno; Akio Ohishi; Mitsukazu Gotoh
Journal of Clinical Oncology | 2017
Yuki Owada; Satoshi Muto; Hironori Takagi; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Jun Ohsugi; Daisuke Tanaka; Emi Ito; Hideaki Nanamiya; Jun-ichi Imai; Takao Isogai; Shinya Watanabe; Hiroyuki Suzuki